Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers

Abstract

The amyloid β peptide (Aβ) is a key player in the etiology of Alzheimer disease (AD), yet a systematic investigation of its molecular interactions has not been reported. Here we identified by quantitative mass spectrometry proteins in human brain extract that bind to oligomeric Aβ1-42 (oAβ1-42) and/or monomeric Aβ1-42 (mAβ1-42) baits. Remarkably, the cyclic neuroendocrine peptide somatostatin-14 (SST14) was observed to be the most selectively enriched oAβ1-42 binder. The binding interface comprises a central tryptophan within SST14 and the N-terminus of Aβ1-42. The presence of SST14 inhibited Aβ aggregation and masked the ability of several antibodies to detect Aβ. Notably, Aβ1-42, but not Aβ1-40, formed in the presence of SST14 oligomeric assemblies of 50 to 60 kDa that were visualized by gel electrophoresis, nanoparticle tracking analysis and electron microscopy. These findings may be relevant for Aβ-directed diagnostics and may signify a role of SST14 in the etiology of AD.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Hansen Wang

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    Hansen Wang, Holds provisionary US patent on amyloid-beta binding polypeptides based on the results of this study (filing number 62/451,309)..
  2. Lisa D Muiznieks

    Molecular Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada
    Competing interests
    No competing interests declared.
  3. Punam Ghosh

    Department of Medical Biophysics, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  4. Declan Williams

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  5. Michael Solarski

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  6. Andrew Fang

    Department of Biochemistry, University of Alberta, Edmonton, Canada
    Competing interests
    No competing interests declared.
  7. Alejandro Ruiz-Riquelme

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6581-7132
  8. Régis Pomès

    Molecular Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3068-9833
  9. Joel C Watts

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  10. Avi Chakrabartty

    Department of Medical Biophysics, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  11. Holger Wille

    Department of Biochemistry, University of Alberta, Edmonton, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5102-8706
  12. Simon Sharpe

    Molecular Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada
    Competing interests
    No competing interests declared.
  13. Gerold Schmitt-Ulms

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    For correspondence
    g.schmittulms@utoronto.ca
    Competing interests
    Gerold Schmitt-Ulms, Holds provisionary US patent on amyloid-beta binding polypeptides based on the results of this study (filing number 62/451,309).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6962-0919

Funding

Canadian Institutes of Health Research

  • Gerold Schmitt-Ulms

Ontario Centres for Excellence

  • Simon Sharpe
  • Gerold Schmitt-Ulms

Alberta Innovates Bio Solutions (201600028)

  • Holger Wille
  • Gerold Schmitt-Ulms

Heart and Stroke Foundation of Canada (G-15-0009148)

  • Simon Sharpe

Canada Foundation for Innovation

  • Gerold Schmitt-Ulms

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The work was performed in strict accordance with University of Toronto animal care and biosafety recommendations. All mice were handled according to procedures approved (AUP4183.3) by the animal care committee at University Health Network overseeing work at the Krembil Discovery Centre (Toronto). The handling of samples and reagents followed biosafety procedures approved (208-S06-2) by the University of Toronto Biosafety Program.

Copyright

© 2017, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,787
    views
  • 557
    downloads
  • 37
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hansen Wang
  2. Lisa D Muiznieks
  3. Punam Ghosh
  4. Declan Williams
  5. Michael Solarski
  6. Andrew Fang
  7. Alejandro Ruiz-Riquelme
  8. Régis Pomès
  9. Joel C Watts
  10. Avi Chakrabartty
  11. Holger Wille
  12. Simon Sharpe
  13. Gerold Schmitt-Ulms
(2017)
Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
eLife 6:e28401.
https://doi.org/10.7554/eLife.28401

Share this article

https://doi.org/10.7554/eLife.28401

Further reading

    1. Biochemistry and Chemical Biology
    Jianheng Fox Liu, Ben R Hawley ... Samie R Jaffrey
    Tools and Resources

    N 6,2’-O-dimethyladenosine (m6Am) is a modified nucleotide located at the first transcribed position in mRNA and snRNA that is essential for diverse physiological processes. m6Am mapping methods assume each gene uses a single start nucleotide. However, gene transcription usually involves multiple start sites, generating numerous 5’ isoforms. Thus, gene-level annotations cannot capture the diversity of m6Am modification in the transcriptome. Here, we describe CROWN-seq, which simultaneously identifies transcription-start nucleotides and quantifies m6Am stoichiometry for each 5’ isoform that initiates with adenosine. Using CROWN-seq, we map the m6Am landscape in nine human cell lines. Our findings reveal that m6Am is nearly always a high stoichiometry modification, with only a small subset of cellular mRNAs showing lower m6Am stoichiometry. We find that m6Am is associated with increased transcript expression and provide evidence that m6Am may be linked to transcription initiation associated with specific promoter sequences and initiation mechanisms. These data suggest a potential new function for m6Am in influencing transcription.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Joar Esteban Pinto Torres, Mathieu Claes ... Yann G-J Sterckx
    Research Article

    African trypanosomes are the causative agents of neglected tropical diseases affecting both humans and livestock. Disease control is highly challenging due to an increasing number of drug treatment failures. African trypanosomes are extracellular, blood-borne parasites that mainly rely on glycolysis for their energy metabolism within the mammalian host. Trypanosomal glycolytic enzymes are therefore of interest for the development of trypanocidal drugs. Here, we report the serendipitous discovery of a camelid single-domain antibody (sdAb aka Nanobody) that selectively inhibits the enzymatic activity of trypanosomatid (but not host) pyruvate kinases through an allosteric mechanism. By combining enzyme kinetics, biophysics, structural biology, and transgenic parasite survival assays, we provide a proof-of-principle that the sdAb-mediated enzyme inhibition negatively impacts parasite fitness and growth.